{"entity":{"id":"jskn003","kind":"drug","name":"JSKN003","aka":[],"tldr":"JSKN003 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.","summary":"JSKN003 is an investigational agent whose form is not stated in the registry developed by Jiangsu Alphamab Biopharmaceuticals and Shanghai JMT-Bio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: JSKN003 should be administered intravenously on the first day of each 3-week cycle. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06079983 (JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects) and NCT06846437 (JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer. The largest, NCT05744427, plans to enrol 725 participants with primary completion was scheduled for 2026-07-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of JSKN003","url":"https://clinicaltrials.gov/search?intr=JSKN003"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["alphamab","cspc"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06079983","nct06846437","nct05744427"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jskn003/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"},{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}],"trial":[{"id":"nct07384377","kind":"trial","name":"JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Iri","route":"/trials/nct07384377/"},{"id":"nct06846437","kind":"trial","name":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","route":"/trials/nct06846437/"},{"id":"nct06079983","kind":"trial","name":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","route":"/trials/nct06079983/"},{"id":"nct05744427","kind":"trial","name":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","route":"/trials/nct05744427/"}]}}